EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Real‐World Effectiveness and Safety of Finerenone in People With Type 2 Diabetes and Chronic Kidney Disease: A Spanish Multicentre Retrospective Observational Study ( MEDFINE ‐ RWD )

Real-World-Wirksamkeit und Sicherheit von Finerenon bei Menschen mit Typ-2-Diabetes und chronischer Nierenerkrankung: spanische multizentrische retrospektive Beobachtungsstudie (MEDFINE-RWD)

Oscar Moreno-Pérez iD, Antonio Tejera-Muñoz, Patricia Tomás-Gómez, Federico Vázquez-San Miguel, Virginia Soria-Utrilla, Ada María Roldán-Sánchez, Maya Sánchez-Baya iD, Jersy Cárdenas-Salas, Blanca Timón-Vázquez, Juan J Gorgojo-Martínez, Ines Modrego-Pardo, Irea Fernández-Xove und 2 weitere

Diabetes, Obesity and Metabolism · 2026-10 · 28 (10) · 9461-9472

DOI: 10.1111/dom.71160 ↗

Auf einen Blick

Bei 844 Personen mit Typ-2-Diabetes und CKD war Finerenon im Alltag mit einer Reduktion der Albuminurie verbunden. Nach 6 Monaten erreichten 52,7 % den primären Endpunkt.

Fragestellung

Wie wirksam und sicher ist Finerenon in der Routineversorgung bei Menschen mit Typ-2-Diabetes und CKD?

Methode

Multizentrische retrospektive Beobachtungsstudie in 8 spanischen Zentren; Einschluss ab Juni 2024 bis Dezember 2025; Analyse mit multipler logistischer Regression.

Ergebnisse

844 Teilnehmende; medianes Alter 72 Jahre; medianes Follow-up 184 Tage. UACR median um 34,5 % reduziert (p < 0,001); primärer Endpunkt bei 52,7 %. Hyperkaliämie 4,8 %, MAKE 0,9 %, MACE 1,1 %.

Schlussfolgerung der Autor:innen

In der Routineversorgung war Finerenon mit einer deutlichen Senkung der Albuminurie verbunden. Die Persistenz war hoch und das Sicherheitsprofil günstig, unabhängig von renoprotektiven Begleittherapien oder KDIGO-Risiko.

Kernaussagen

  • UACR median um 34,5 % reduziert
  • Primärer Endpunkt bei 52,7 % erreicht
  • Hyperkaliämie 4,8 %, MAKE 0,9 %, MACE 1,1 %

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Multizentrische Studie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 30.07.2026. Verfasst von Oscar Moreno-Pérez und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Nutrition, General University Hospital Dr. Balmis of Alicante, Institute of Health and Biomedical Research of Alicant…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic, Naphthyridines, Diabetic Nephropathies. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Although finerenone has shown efficacy in randomized trials, evidence from routine clinical practice remains limited. We aimed to assess the real‐world effectiveness and safety of finerenone in people with type 2 diabetes (PWT2D) and chronic kidney disease (CKD), with a particular focus on residual cardiorenal risk as reflected by changes in urinary albumin‐to‐creatinine ratio (UACR). Materials and Methods MEDFINE‐RWD was a multicentre, retrospective study across eight Spanish centres, enrolling patients initiating finerenone (June 2024–December 2025). The primary endpoint was a ≥ 30% reduction in UACR. Multivariable logistic regression identified response predictors. Secondary outcomes included safety (hyperkalaemia ≥ 5.5 mmol/L, major kidney [MAKE] and cardiovascular events [MACE]).

Results

Among 844 participants (median age 72 years; median follow‐up 184 days; 76.8% male; baseline eGFR 49 mL/min/1.73 m 2 ; UACR 285 mg/g; 77.8% were at high/very high KDIGO risk), finerenone was associated with a 34.5% median UACR reduction at 6 months ( p < 0.001), despite intensive SGLT2 inhibitors (88.4%) and GLP‐1 receptor agonists (35.7%) use. The primary endpoint was achieved by 52.7%, consistently across background renoprotection or baseline KDIGO risk strata. Predictors of response were age ≥ 70 (aOR 2.12), baseline UACR > 245 mg/g (aOR 1.94), and BMI > 27 kg/m 2 (aOR 1.84), while insulin use was associated with lower response odds. Treatment persistence was 89.5%, with low incidences of hyperkalaemia (4.8%), MAKE (0.9%), and MACE (1.1%).

Conclusions

In real‐world practice, finerenone was associated with a substantial reduction in albuminuria. Finerenone demonstrated high persistence and a favourable safety profile, irrespective of baseline renoprotective regimens or KDIGO risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Renal Insufficiency, ChronicNaphthyridinesDiabetic NephropathiesMineralocorticoid Receptor AntagonistsHumansMaleFemaleRetrospective StudiesAgedSpainMiddle AgedTreatment OutcomeAlbuminuriaAged, 80 and overGlomerular Filtration Rate

Stichwörter der Autor:innen

MEDFINEchronic kidney diseasefinerenoneobservational studyreal world datatype 2 diabetes

Substanzen

finerenoneNaphthyridinesMineralocorticoid Receptor Antagonists

Autor:innen und Institutionen

  • Department of Endocrinology and Nutrition, General University Hospital Dr. Balmis of Alicante, Institute of Health and Biomedical Research of Alicante (ISABIAL), Alicante, Spain.
  • Department of Clinical Medicine, Miguel Hernández University, Elche, Spain.
  • University Centre for Health Sciences-HM Hospitals (CUHMED), Camilo Jose Cela University, Madrid, Spain.
  • Endocrinology Unit, University Hospital of Torrecárdenas, Almería, Spain.
  • Department of Endocrinology and Nutrition, Germans Trias i Pujol University Hospital, Badalona, Spain.
  • Department of Endocrinology and Nutrition, Regional University Hospital of Malaga, Biomedical Research Institute of Malaga (IBIMA), Faculty of Medicine, University of Malaga, Malaga, Spain.

ORCID-Profile: Oscar Moreno-Pérez, Maya Sánchez-Baya, Rebeca Reyes-García

Zitieren

APA

Moreno-Pérez, O., Tejera-Muñoz, A., Tomás-Gómez, P., Vázquez-San Miguel, F., Soria-Utrilla, V., Roldán-Sánchez, A. M., Sánchez-Baya, M., Cárdenas-Salas, J., Timón-Vázquez, B., Gorgojo-Martínez, J. J., Modrego-Pardo, I., Fernández-Xove, I., Fernández-García, J. C., & Reyes-García, R. (2026). Real‐World Effectiveness and Safety of Finerenone in People With Type 2 Diabetes and Chronic Kidney Disease: A Spanish Multicentre Retrospective Observational Study ( MEDFINE ‐ RWD ). Diabetes, Obesity and Metabolism, 28(10), 9461-9472. https://doi.org/10.1111/dom.71160

Vancouver

Moreno-Pérez O, Tejera-Muñoz A, Tomás-Gómez P, Vázquez-San Miguel F, Soria-Utrilla V, Roldán-Sánchez AM, et al. Real‐World Effectiveness and Safety of Finerenone in People With Type 2 Diabetes and Chronic Kidney Disease: A Spanish Multicentre Retrospective Observational Study ( MEDFINE ‐ RWD ). Diabetes, Obesity and Metabolism. 2026;28(10):9461-9472. doi:10.1111/dom.71160

BibTeX
@article{MorenoPrez2026,
  author = {Moreno-Pérez, Oscar and Tejera-Muñoz, Antonio and Tomás-Gómez, Patricia and Vázquez-San Miguel, Federico and Soria-Utrilla, Virginia and Roldán-Sánchez, Ada María and Sánchez-Baya, Maya and Cárdenas-Salas, Jersy and Timón-Vázquez, Blanca and Gorgojo-Martínez, Juan J and Modrego-Pardo, Ines and Fernández-Xove, Irea and Fernández-García, Jose Carlos and Reyes-García, Rebeca},
  title = {Real‐World Effectiveness and Safety of Finerenone in People With Type 2 Diabetes and Chronic Kidney Disease: A Spanish Multicentre Retrospective Observational Study ( MEDFINE ‐ RWD )},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  volume = {28},
  number = {10},
  pages = {9461--9472},
  doi = {10.1111/dom.71160}
}
Kostenlos starten →